South AfricaTuberculosis profile
Population  2017 57 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 22 (20–24) 39 (35–43)
Mortality (HIV+TB only) 56 (39–77) 99 (68–135)
Incidence  (includes HIV+TB) 322 (230–428) 567 (406–754)
Incidence (HIV+TB only) 193 (137–258) 340 (241–455)
Incidence (MDR/RR-TB)** 14 (8.9–20) 25 (16–36)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 18 (17–19) 117 (95–138) 135 (108–161)
Males 20 (18–21) 167 (130–204) 187 (143–231)
Total 38 (34–42) 284 (202–366) 322 (230–428)
TB case notifications, 2017  
Total cases notified 227 224
Total new and relapse 220 163
          - % tested with rapid diagnostics at time of diagnosis 66%
          - % with known HIV status 94%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 65%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 68% (51–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.25 (0.16–0.35)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 123 148 60%
          - on antiretroviral therapy 109 799 89%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  7 700
(6 000–9 400)
Estimated % of TB cases with MDR/RR-TB 3.4% (2.5–4.3) 7.1% (4.8–9.5)  
% notified tested for rifampicin resistance 64% 68% 150 548
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 15 986, XDR-TB: 747
Patients started on treatment **** MDR/RR-TB: 10 259, XDR-TB: 463
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 82% 236 702
Previously treated cases, excluding relapse, registered in 2016 62% 5 129
HIV-positive TB cases registered in 2016 80% 133 710
MDR/RR-TB cases started on second-line treatment in 2015 55% 9 750
XDR-TB cases started on second-line treatment in 2015 48% 427
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 53%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
79% (72–86)
TB financing, 2018  
National TB budget (US$ millions) 271
Funding source: 91% domestic, 8% international, <1% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-12-11 Data: www.who.int/tb/data